Impact of dexmedetomidine administration timing on postoperative delirium in elderly patients with lower limb fractures: a study protocol for a randomised controlled trial Authors: Meilan Chen, Yingmei Ren, Xuan Wu, Wei Yuan, Shijie Ji, Xiaolin Yang Published: 2026 ABSTRACT AbstractIntroductionPostoperative delirium (POD) is a prevalent perioperative complication among geriatric orthopaedic patients, leading to extended hospitalisation, escalated medical expenditures and persistent cognitive impairment. Although existing studies suggest that dexmedetomidine can reduce the risk of POD, the optimal timing of administration remains undetermined.Methods and analysisThis is a prospective, randomised controlled trial. Patients aged ≥65 years undergoing lower limb fracture surgery under neuraxial anaesthesia will be randomised into a preoperative administration group, an intraoperative administration group or a control group. The study employed a double-dummy technique, with all patients receiving an intravenous infusion at two time points: 15 min prior to neuraxial anaesthesia puncture (T1) and 15 min prior to skin incision (T2). The preoperative group will receive dexmedetomidine at T1 and placebo at T2; the intraoperative group will receive placebo at T1 and dexmedetomidine at T2 and the control group will receive placebo at both T1 and T2. The dexmedetomidine dose is 0.5 µg/kg (infused over ≥10 min), and the placebo is an equivalent volume of 0.9% saline. The primary outcome is the incidence of POD within the first 3 postoperative days. Secondary outcomes include the Mini-Mental State Examination, Leeds Sleep Evaluation Questionnaire, visual analogue scale for resting pain, Activities of Daily Living and Quality of Recovery-15, as well as serum biomarkers (neuron-specific enolase, S100 calcium-binding protein B, interleukin-6, C-reactive protein) measured preoperatively and on postoperative day 1. Additionally, regional cerebral oxygen saturation, Bispectral Index and haemodynamics will be monitored.Ethics and disseminationEthical approval for this protocol was obtained from the Medical Ethics Committee of Rugao People’s Hospital (approval number: 2025-YJ-011-01). We plan to publish the study findings in peer-reviewed journals and present them at relevant scientific meetings.Trial registration numberChiCTR2500114299.Keywords: Postoperative Delirium, Aged, Anaesthesia in orthopaedics Strengths and limitations of this study This is a prospective, randomised controlled trial designed to investigate the impact of dexmedetomidine administration timing on postoperative delirium (POD) in elderly patients. This is a prospective, randomised controlled trial designed to investigate the impact of dexmedetomidine administration timing on postoperative delirium (POD) in elderly patients. As far as we know, this is the first clinical study to specifically compare the efficacy of different dexmedetomidine infusion timings (preoperative vs intraoperative) in aged patients undergoing lower limb fracture surgery under neuraxial anaesthesia. As far as we know, this is the first clinical study to specifically compare the efficacy of different dexmedetomidine infusion timings (preoperative vs intraoperative) in aged patients undergoing lower limb fracture surgery under neuraxial anaesthesia. The study integrates the analysis of inflammatory mediators (C-reactive protein, interleukin-6) and neuronal injury markers (S100 calcium-binding protein B, neuron-specific enolase) to provide objective biological evidence for the anti-inflammatory and neuroprotective mechanisms of dexmedetomidine and their association with clinical outcomes. The study integrates the analysis of inflammatory mediators (C-reactive protein, interleukin-6) and neuronal injury markers (S100 calcium-binding protein B, neuron-specific enolase) to provide objective biological evidence for the anti-inflammatory and neuroprotective mechanisms of dexmedetomidine and their association with clinical outcomes. The primary limitation is the single-centre design, which may limit the generalisability of the findings to different medical settings or populations. The primary limitation is the single-centre design, which may limit the generalisability of the findings to different medical settings or populations. The exclusion of patients with pre-existing dementia was necessary to ensure the diagnostic accuracy of POD assessments, although this inevitably restricts generalisability of our findings for this high-risk subgroup. The exclusion of patients with pre-existing dementia was necessary to ensure the diagnostic accuracy of POD assessments, although this inevitably restricts generalisability of our findings for this high-risk subgroup. Background The accelerating ageing of the global population has led to a consistent rise in the volume of geriatric patients undergoing surgery.1 Due to osteoporosis, decline in physical function and other factors, lower limb fractures are particularly common among elderly patients,2,4 and surgery is the primary treatment method.5 However, postoperative delirium (POD) represents a frequent and debilitating complication in these patients, with an incidence of up to 30%.6 POD not only increases the length of hospital stays but is also closely associated with long-term cognitive decline and mortality, imposing a substantial burden on healthcare systems.7 According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition,8 POD is defined as an acute disturbance in attention and awareness accompanied by a change in cognition, which is reversible. Clinically, it can be classified into hyperactive, hypoactive or mixed subtypes, with the hypoactive form being particularly prevalent yet easily overlooked in geriatric patients.9 10 Established independent risk factors include advanced age (≥65 years), preoperative comorbidities, hypoalbuminaemia, pre-existing dementia and an American Society of Anesthesiologists (ASA) physical status of III or higher.11 Despite the identification of these risk factors, there is currently a lack of effective and specific intervention strategies to minimise POD risk in this vulnerable population. Current pathophysiological evidence suggests that neuroinflammation,12 neuronal injury13 and sleep–wake cycle disruption14 play pivotal roles in the development of POD. These pathological processes are often accompanied by elevated levels of brain injury biomarkers (eg, S100 calcium-binding protein B (S100β), neuron-specific enolase (NSE)) and inflammatory cytokines (eg, C-reactive protein (CRP), interleukin-6 (IL-6)).15 Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, has demonstrated the potential to attenuate these pathological responses.16 17 Mechanistically, it activates presynaptic α₂-receptors to inhibit norepinephrine release for analgesia and postsynaptic receptors to inhibit sympathetic tone for sedation.18 Furthermore, it acts on the locus coeruleus to induce a state resembling physiological sleep (often termed ‘biomimetic sleep’). Accumulating evidence indicates that dexmedetomidine exerts protective effects on the brain, heart and kidneys19 20 and improves patient outcomes through its opioid-sparing21 and anti-inflammatory properties.22 However, some studies have also shown that intravenous infusion of dexmedetomidine can increase the incidence of hypotension and bradycardia. The occurrence of these haemodynamic adverse events may be closely related to the dosage and, crucially, the timing of administration.23 24 Although current evidence supports the efficacy of dexmedetomidine in reducing POD, the optimal timing of administration remains undetermined. Consequently, the objective of this trial is to evaluate the preventive effectiveness and safety profile of various dexmedetomidine administration schedules in mitigating POD among older adults receiving lower limb fracture surgery. Methods and analysis Study design This study is designed as a single-centre, prospective, randomised, double-blind, placebo-controlled trial. The primary objective is to evaluate how different dexmedetomidine administration timings (preoperative vs intraoperative) affect the development of POD in patients aged ≥65 years, thereby identifying the optimal clinical window. Ethical authorisation for this research was granted by the Rugao People’s Hospital Medical Ethics Committee (Approval No. 2025-YJ-011-01), with prospective registration completed at the Chinese Clinical Trial Registry (ChiCTR2500114299). The design of this study follows the relevant standards for randomised trials.25 26 The study flow and schedule are detailed in figure 1 and table 1, respectively. Recruitment is scheduled to commence in March 2026, with study completion expected by December 2027. Eligible patients who provide written informed consent will be randomised in a 1:1:1 ratio into the preoperative administration group, intraoperative administration group or control group. Flow chart of the trial procedure. ADL, Activities of Daily Living; CRP, C-reactive protein; IL-6, interleukin-6; LSEQ, Leeds Sleep Evaluation Questionnaire; MMSE, Mini-Mental State Examination; NSE, neuron-specific enolase; POD, postoperative delirium; QoR-15, Quality of Recovery-15; S100β, S100 calcium-binding protein B; VAS, visual analogue scale. Table 1Schedule of process of trialTime pointsStudy periodBaselineTreatmentFollow-up phaseDay −1Day 0Day 1Day 3DischargeDay 90EnrolmentDemographyX Baseline dataX Eligibility screenX Eligibility screenX RandomisationXIntervention Preoperative groupX Intraoperative groupX Control groupX Assessments Intraoperative dataX Blood samples for biomarkersXX Nausea and vomitingXXXX CAMXXX MMSE scoresXXXX VAS scoresXXXX LSEQ scoresXXXX ADL scoresXXXX QoR-15 scoresXXXX Adverse eventsXXXXX All-cause MortalityXXXXXADL, Activities of Daily Living; CAM, confusion assessment method; LSEQ, Leeds Sleep Evaluation Questionnaire; MMSE, Mini-Mental State Examination; QoR-15, Quality of Recovery-15; VAS, visual analogue scale. Schedule of process of trial ADL, Activities of Daily Living; CAM, confusion assessment method; LSEQ, Leeds Sleep Evaluation Questionnaire; MMSE, Mini-Mental State Examination; QoR-15, Quality of Recovery-15; VAS, visual analogue scale. Written informed consent was obtained from all patients preoperatively. No patients were enrolled intraoperatively. After hospital admission, eligible patients with stable vital signs and adequate decision-making capacity were fully informed by an independent researcher and provided voluntary written consent. For patients who were illiterate or unable to write due to low educational level, consent was obtained from their legally authorised representative under the approved ethical protocol. Study setting The study is set to take place within the Department of Anesthesiology and Department of Orthopedics, Rugao People’s Hospital, Jiangsu Province, China. Inclusion and exclusion criteria Inclusion Scheduled for lower limb fracture surgery under neuraxial anaesthesia. Scheduled for lower limb fracture surgery under neuraxial anaesthesia. Aged ≥65 years. Aged ≥65 years. Capable of effective communication and able to complete preoperative assessments, including the Mini-Mental State Examination (MMSE), visual analogue scale (VAS), Leeds Sleep Evaluation Questionnaire (LSEQ), Activities of Daily Living (ADL) and Quality of Recovery-15 (QoR-15). Capable of effective communication and able to complete preoperative assessments, including the Mini-Mental State Examination (MMSE), visual analogue scale (VAS), Leeds Sleep Evaluation Questionnaire (LSEQ), Activities of Daily Living (ADL) and Quality of Recovery-15 (QoR-15). Provision of written informed consent by the patient or their legal surrogate. Provision of written informed consent by the patient or their legal surrogate. ASA physical status I–III. ASA physical status I–III. Exclusion Refusal to participate or provide informed consent. Refusal to participate or provide informed consent. Presence of organic brain diseases, such as brain trauma, intracranial haematoma or congenital brain development abnormalities. Presence of organic brain diseases, such as brain trauma, intracranial haematoma or congenital brain development abnormalities. Patients with dementia or known psychiatric disorders. Patients with dementia or known psychiatric disorders. Patients with aphasia or hearing impairment. Patients with aphasia or hearing impairment. Known allergy or hypersensitivity to dexmedetomidine. Known allergy or hypersensitivity to dexmedetomidine. Severe preoperative bradycardia (heart rate <50 beats/min). Severe preoperative bradycardia (heart rate <50 beats/min). Severe hepatic or renal dysfunction. Severe hepatic or renal dysfunction. Patients with preoperative delirium identified by 3D-CAM screening during the preoperative visit. Patients with preoperative delirium identified by 3D-CAM screening during the preoperative visit. Randomisation and blinding The randomisation sequence will be generated by an independent statistician using a computer-generated random number list, and patients were randomly assigned to three groups in a 1:1:1 ratio. The randomisation results were sealed in opaque envelopes, and patients, the anaesthesiologists in charge and individuals responsible for outcome assessment remained unaware of the treatment allocation. Unblinding by the anaesthesiologist is permitted only if a severe adverse event requiring emergency management occurs intraoperatively (eg, severe hypotension or bradycardia refractory to conventional treatment). To maintain blinding integrity despite the potential physiological effects of dexmedetomidine, a strict separation of clinical and research roles will be implemented. Study drugs will be prepared in identical syringes by an independent research assistant not involved in anaesthesia management or data collection. While intraoperative haemodynamic fluctuations may be observed by the attending anaesthesiologist, the outcome assessors responsible for POD screening and secondary assessments will be completely blinded to the intraoperative grouping and anaesthesia records. These assessors will be physically isolated from the operating environment and are strictly prohibited from accessing any real-time or recorded vital signs data until the conclusion of the study. Intervention and grouping The study drug is dexmedetomidine hydrochloride injection (80 µg/20 mL; Sichuan Beite Pharmaceutical, China). Patients in the experimental groups will receive a single intravenous infusion at a dose of 0.5 µg/kg, with the infusion duration controlled at ≥10 min. To maintain strict blinding, a double-dummy technique will be employed where all patients receive infusions at two distinct time points: Time point 1 (T1), commencing 15 min prior to neuraxial anaesthesia puncture; and Time point 2 (T2), commencing 15 min prior to skin incision. The preoperative group will receive dexmedetomidine at T1 and an equivalent volume of 0.9% saline (placebo) at T2; the intraoperative group will receive placebo at T1 and dexmedetomidine at T2; and the control group will receive placebo at both T1 and T2. Infusion rates and durations remain identical across groups, and a 3-month postoperative follow-up will be conducted via telephone interview to assess long-term outcomes. Standardised haemodynamic management will be strictly enforced during the infusion and perioperative period: if the heart rate drops below 50 bpm, 0.5 mg of intravenous atropine will be administered; if the mean arterial pressure decreases by >20% from baseline, phenylephrine or ephedrine will be used. All infusion volumes will remain identical across groups. A 3-month postoperative follow-up will be conducted via telephone interview by a blinded researcher to assess long-term recovery outcomes. Anaesthesia On arrival in the operating theatre, routine peripheral venous access will be established, and patients will undergo combined spinal-epidural anaesthesia (CSEA) in the lateral decubitus position. To facilitate the lateral decubitus position for CSEA without resorting to systemic sedation, all patients will receive an ultrasound-guided fascia iliaca compartment block. The block will be performed using a mixture of 10 mL 2% lidocaine and 10 mL (113 mg) bupivacaine liposome, diluted with 0.9% normal saline to a total volume of 30 mL. No additional systemic sedatives or opioids will be administered for positioning, thereby minimising pharmacological interference with the assessment of POD. CSEA was selected as the sole anaesthetic technique for this trial for two reasons. First, neuraxial anaesthesia is routinely used for lower limb fracture surgery in older adults at our centre and therefore reflects local clinical practice. Second, restricting enrolment to a single anaesthetic technique reduces heterogeneity and minimises confounding related to differential anaesthetic exposure, thereby allowing a clearer evaluation of the effect of dexmedetomidine administration timing on POD. The L2–3 or L3–4 interspace will be selected for puncture using the needle-through-needle technique, with an epidural catheter advanced 3–4 cm cephalad. Following confirmation of subarachnoid placement, 1.6–2.2 mL of 0.75% isobaric bupivacaine will be injected (with the needle bevel cephalad) at a rate of 1 mL/5 s, targeting a sensory block level of T8. In cases of puncture failure or inadequate block (sensory level